ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 37

Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis

Yanli Tong1, Yunqiang Bai 2, Yi Zhao 2, Yi Liu 2 and Yubin Luo 2, 1Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China (People's Republic), 2Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China (People's Republic)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-CCP antibodies, biomarkers and prevention, microbe, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Intestinal microbial dysbiosis in patients with rheumatoid arthritis (RA) has raised the interest in studying the role of intestinal microbes in the pathogenesis of RA. Animals studies indicate that intestinal microbiota changes prior to the onset of visible inflammatory arthritis. Here, we undertook this study to clarify the intestinal microbiota changes in individuals at high risk for RA with the aim to identify bacteria biomarkers associated with the progression of RA.

Methods: High-risk for RA individuals were defined as having a positive serum antibody for anti-cyclic citrullinated peptide (CCP), without reported arthritis symptoms at the time of enrollment. RA patients were diagnosed according to the American College of Rheumatology (ACR) 2010 classification for RA. Age and gender matched anti-CCP negative healthy individuals were recruited as controls. Individuals having a history of antibiotics treatment in the last six months or other conditions that may affect the study were excluded. The 16S ribosomal RNA of fecal samples from 31 RA patients, 42 high-risk individuals and 38 healthy controls (HC) were sequenced and analyzed.

Results: Alpha diversity analysis showed that the intestinal microbiota communities in high-risk group (“pre” group) had a lower community diversity (Shannon index) than the healthy controls (Fig.1A). Beta diversity using principal coordinate analysis (PCoA) revealed that the intestinal microbiota was significantly different between groups (Fig.1B). Interestingly, we observed that the intestinal microbiota communities dynamically shifted from HCs to high-risk individuals (Pre) to RA patients.

The majority of species (437) were shared by all groups. 35 species were found only in high-risk individuals and RA patients (Fig. 2A). Besides, the abundance of the microflora variant between groups. At the phylum level, the abundance of Bacteroidetes gradually decreased from HCs to high-risk individuals to RA patients. The abundance of Saccharibacteria were particularly higher in high-risk individuals than in both RA patients and HCs (Fig. 2B). Further to the family level, Bacteroidaceae, Pseudomonadaceae and Pasteurellaceae showed the same trend of gradual reduction from the HCs to high-risk individuals and to RA patients. On the contrary, an enriched abundance of Streptococcaceae, Lactobacillaceae, Enterococcaceae and Leuconostocaceae were seen in RA patients (Fig. 2C).

To determine taxonomic biomarkers that characterize the differences in the progression of RA, linear discriminant analysis (LDA) analysis was performed (Fig. 3A). We identified potential disease stage specific bacteria. A marker panel of six bacteria species was selected, which had an AUC of 0.78 (95%CI=0.66-0.9) in discriminating RA patients from HCs (Fig. 3B and 3C).

Conclusion: The intestinal microbiota changed gradually during disease progression of human RA. Intestinal dysbiosis occurs prior to the onset of arthritis symptoms in individuals with positive anti-CCP antibody. Identifying the specific microbes characterize individuals at preclinical stage would provide a useful tool for early detection and intervention of RA.


Fig1

Fig.1 Alpha diversity -A- and beta diversity -B- analysis of the intestinal microbiota communities in rheumatoid arthritis -RA- patients, high-risk individuals for RA -Pre- and healthy controls -HC-.


Fig2

Fig.2 Differential and variant abundance of intestinal bacteria in rheumatoid arthritis -RA- patients, high-risk individuals for RA -Pre- and healthy controls -HC-. -A- Venn diagram showing the number of shared and specific species in the three groups of individuals. Bacteria with different abundance in the three groups at the phylum level -B- and the family level -C-.


Fig3

Fig.3 The discriminant taxonomic biomarkers that characterize the stages in the progression of RA. -A- LDA analysis showing the most discriminate bacteria for the specificity of each group. Bacterial marker of six bacteria species -B- yield an AUC of 0.78-95%CI=0.66-0.9- with a specificity of 89% and sensitivity of 65% in discriminating RA patients from healthy controls -C-.


Disclosure: Y. Tong, None; Y. Bai, None; Y. Zhao, None; Y. Liu, None; Y. Luo, None.

To cite this abstract in AMA style:

Tong Y, Bai Y, Zhao Y, Liu Y, Luo Y. Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/intestinal-microbiota-dynamics-in-the-progression-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intestinal-microbiota-dynamics-in-the-progression-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology